Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
-
PGA Frac Ball
Contact UsPGA fully degradable frac plug ball is a series of frac plug balls developed based on PGA degradable materials to meet the needs of oil fields under various temperatures and working conditions.
-
Pomegranate Powder Extract (Hull) Ellagic Acid
Contact UsLatin Name: Punica granatum L
Synonyms:
Part of Used: Hull
Specifications: Ellagic Acid 80% HPLC
Appearance:
Application:Food Supplements/Nutritional Supplement/Functional Food/Pharmaceutical -
Metal ropes
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
Reviews
There are no reviews yet.